Endoscopic Retrograde Cholangiopancreatography Market Summary
As per MRFR Analysis, the Endoscopic Retrograde Cholangiopancreatography Market was valued at 2.28 USD Billion in 2024 and is projected to reach 5.82 USD Billion by 2034, growing at a CAGR of 9.80% from 2025 to 2034. The market is driven by the rising application of ERCP for diagnosing and treating pancreatobiliary diseases, with increasing incidences of gastrointestinal disorders contributing to market growth. The demand for ERCP procedures is further fueled by an aging population and the prevalence of chronic biliary conditions.
Key Market Trends & Highlights
The Endoscopic Retrograde Cholangiopancreatography market is witnessing significant growth due to various factors.
- Market Size in 2024: 2.28 USD Billion.
- Projected Market Size by 2034: 5.82 USD Billion.
- CAGR from 2025 to 2034: 9.80%.
- Dominant Segment: Biliary Sphincterotomy in procedures.
Market Size & Forecast
2024 Market Size: USD 2.28 Billion
2025 Market Size: USD 2.51 Billion
2034 Market Size: USD 5.82 Billion
CAGR (2025-2034): 9.80%
Largest Regional Market Share in 2024: North America.
Major Players
Key players include Olympus Corporation, Fujifilm Holdings Corporation, STERIS PLC, Cook Medical, Boston Scientific Corporation, CONMED Corporation, HOYA Group, Q3 Medical Devices Limited, Ambu Inc., and Medtronic Plc.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Endoscopic Retrograde Cholangiopancreatography Market Trends
Rising application of ERCP is driving the market growth
ERCP, also known as endoscopic retrograde cholangiopancreatography, is a method for identifying and treating problems with the pancreas, liver, gallbladder, and bile ducts. Endoscopic retrograde cholangiopancreatography (ERCP) is a procedure for diagnosing and treating pancreatobiliary diseases that combines luminal endoscopy with imaging based on fluoroscopy. It combines the use of an endoscope, a protracted, bendable, and illuminated tube, and X-ray technology. Undiagnosed stomach pain or jaundice, which causes the skin and eyes to turn yellow, may be the result of something that can be found out using ERCP.
If there is pancreatitis or liver, pancreas, or bile duct cancer, it can be used to learn more about such conditions. Endoscopic retrograde cholangiopancreatography (ERCP) can also detect diseases including bile duct obstructions or stones, as well as liquid discharge from the bile or pancreatic ducts. Other disorders that might be found with an ERCP include tumours, obstructions or limitations of the pancreatic ducts, and pollution in the bile ducts. Consequently, the market CAGR for endoscopic retrograde cholangiopancreatography is expanding.
Various organs of the digestive system, including the liver, pancreas, and gallbladder, are affected by gastrointestinal (Gl) illnesses. Gl diseases are a major contributor to worldwide morbidity and mortality and have a profound impact on millions of people. For instance, the 2019 International Foundation for Gastrointestinal Disorders Report states that GED affects roughly one-third of the population and is a major cause of bleeding issues, which is what is driving the expansion of the  market. The National Institutes of Health invested up to $1.6 billion in Gl research in 2017; Gl diseases impact 60–70 million Americans annually. Primary biliary cholangitis (PBC) incidence, on the other hand, ranges from 5.8 to 15 cases per million people. The governments' attention has been called by a significant increase in the fatality rate, and as a result, the demand for treatment is expected to rise over the predicted period.
The usage of endoscopic equipment in the field of ERCP has increased in tandem with a quicker rate of population ageing worldwide. Visual impairment is occurring more frequently now than it ever has before due to population ageing. Comorbidities such as adenomas, hemangiomas, focal nodular hyperplasia (FNH), and pancreatic cancer have so been noted. The fourth most prevalent type of cancer in the world, pancreatic cancer, is what kills people the most. In the United States, 68.5% of pancreatic cancer diagnoses are made in people over 65, according to the National Cancer Database. The number of old people with gastrointestinal and chronic biliary problems, as well as benign liver and pancreatic tumors, will rise as the elderly population rises. Thus, driving the endoscopic retrograde cholangiopancreatography market revenue.
Endoscopic Retrograde Cholangiopancreatography Market Segment Insights
Endoscopic Retrograde Cholangiopancreatography Procedure Insights
The  endoscopic retrograde cholangiopancreatography market segmentation, based on procedure includes Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Duct Stenting and Others. The biliary sphincterotomy segment dominated the market. The biliary sphincter and the intraduodenal portion of the common bile duct are both severed using a high-frequency current following selective cannulation using a sphincterotome, a specialised knife inserted into the papilla. Biliary endoscopic sphincterotomy (EST), also known as biliary sphincterotomy, is the name of this procedure.
Endoscopic Retrograde Cholangiopancreatography End User Insights
The  endoscopic retrograde cholangiopancreatography market segmentation, based on end user, includes Hospitals & Clinics and Ambulatory Surgical Centers. Hospitals & clinics category generated the most income. This increase can be attributed to the accelerated expansion of the healthcare infrastructure in North America and Europe, which has aided in the financial growth of hospitals. This market is expanding as a result of the increasing patient demand for hospital-based care utilising sphincterotomes and for clinics to provide better preventive care and more advanced treatment choices.
Figure 1  Endoscopic Retrograde Cholangiopancreatography Market, by End User, 2022 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Endoscopic Retrograde Cholangiopancreatography Application Insights
The  endoscopic retrograde cholangiopancreatography market segmentation, based on product includes Bile Duct, Pancreas and Others. The bile duct segment dominated the market. Bile duct, stone, and structure-related disorders are diagnosed and treated with endoscopic retrograde cholangiopancreatography. Gallstones or sludge are the culprits behind the bile duct obstruction. Gallbladder stones are also more common in emerging countries and are influenced by changes in lifestyle.
Endoscopic Retrograde Cholangiopancreatography Product Insights
The  endoscopic retrograde cholangiopancreatography market segmentation, based on product includes Endoscopes (Endotherapy Devices, Catheters, Stents, Balloons, Guiding Wires, Others), Imaging Devices and Energy Devices. The endoscopes segment dominated the market. In the upcoming years, it is anticipated that the market for endoscopic retrograde cholangiopancreatography devices for endoscopes will grow significantly as a result of a growth in gastrointestinal and chronic biliary problems.
Endoscopic Retrograde Cholangiopancreatography Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American endoscopic retrograde cholangiopancreatography market area will dominate this market. This region is expanding as a result of intensive diagnostic imaging research and the rapid introduction of technologically advanced ERCP tools like sphincterotomes. The expansion of government healthcare funding and the presence of important companies like Hobbs Medical Inc. in the area are both contributing to the growth.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 Â ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SHARE BY REGION 2022 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe endoscopic retrograde cholangiopancreatography market accounts for the second-largest market share due to the enormous negative impact biliary and pancreatic problems have on people's general health. These illnesses include Crohn's disease, inflammatory bowel disease, liver disease, pancreatitis, and gastroesophageal reflux disease (GERD). When the diseases have not been discovered in their earliest stages, surgical intervention is necessary to treat these problems in severe cases. Further, the German endoscopic retrograde cholangiopancreatography market held the largest market share, and the UK endoscopic retrograde cholangiopancreatography market was the fastest growing market in the European region.
The Asia-Pacific Endoscopic retrograde cholangiopancreatography Market is expected to grow at the fastest CAGR from 2023 to 2032. The expansion of the healthcare industry is responsible for this growth. The growth of the Endoscopic Retrograde Cholangiopancreatography Market in the Asia-Pacific region is also being fueled by the rising awareness of the use of spincterotomes in the treatment of pancreatic and liver disorders. Moreover, China’s endoscopic retrograde cholangiopancreatography market held the largest market share, and the Indian endoscopic retrograde cholangiopancreatography market was the fastest growing market in the Asia-Pacific region.
Endoscopic Retrograde Cholangiopancreatography Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the endoscopic retrograde cholangiopancreatography market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, endoscopic retrograde cholangiopancreatography industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the endoscopic retrograde cholangiopancreatography industry to benefit clients and increase the market sector. In recent years, the endoscopic retrograde cholangiopancreatography industry has offered some of the most significant advantages to market. Major players in the endoscopic retrograde cholangiopancreatography market attempting to increase market demand by investing in research and development operations include Olympus Corporation (Japan), Fujifilm Holdings, Corporation (Japan), STERIS PLC (UK), Cook Medical (US), Boston Scientific Corporation (US), CONMED Corporation (US), HOYA Group (Japan), Q3 Medical Devices Limited (Ireland), Ambu Inc. (Denmark), Medtronic Plc (Ireland), and Others.
A corporation called Olympus Corp (Olympus) manufactures precise equipment and tools for optical and digital technologies. The company designs, manufactures, and distributes equipment and devices for the healthcare, information, medical, imaging, and other industrial industries. It offers medical systems like endotherapy devices, endoscopes, and endoscopy supplies to aid medical professionals in treating patients, as well as scientific solutions like laser scanning microscopes, remote visual inspection products, industrial and biological microscope systems, and non-destructive testing systems. In February 2020, the FDA has given Olympus' TJF-Q190V duodenoscope approval. The product provides an antiseptic and disposable distal endcap made to reduce contamination and improve machine reprocessing.
ConMed Corp (ConMed) is a producer and distributor of surgical tools and instruments for minimally invasive treatments and monitoring. Arthroscopes, bronchoscopy tools, reconstructive systems, endoscopic ligator kits, trocars, balloons for stone removal, graspers, and scissors, suction irrigation tools, thermal tissue fusion systems, electrosurgical generators, pencil sheaths, smoke evacuation pencils, saws, and blades, endo mechanical instrumentation, and surgical visualization tools are some of the company's main products.
Key Companies in the endoscopic retrograde cholangiopancreatography market include
- Olympus Corporation (Japan)
- Fujifilm Holdings, Corporation (Japan)
- STERIS PLC (UK)
- Cook Medical (US)
- Boston Scientific Corporation (US)
- CONMED Corporation (US)
- HOYA Group (Japan)
- Q3 Medical Devices Limited (Ireland)
- Ambu Inc. (Denmark)
- Medtronic Plc (Ireland)
- Others
Endoscopic Retrograde Cholangiopancreatography Industry Developments
February 2023Â The introduction of the High-Throughput Single-Cell Multiomics Platform by BD was made to increase the scope of scientific discovery.
February 2023Â The FDA has given the LithoVueTM Elite Single-Use Digital Flexible Ureteroscope System by Boston Scientific its approval.
February 2022Â Ambu A/S announced that the Ambu aBox and Ambu aScope Gastro products have received 510(k) regulatory clearance for the American market. The aScope Gastro is a first-of-its-kind sterile, single-use gastroscope that has cutting-edge, enhanced imaging and design characteristics as well as a next-generation display and CPU.
January 2022Â Cook Medical (US) introduced the Instinct Plus endoscopic clipping tool, which is compatible with a duodenoscope and has uses for preventive clipping, anchoring treatments, and defect closure in the GI tract.
Endoscopic Retrograde Cholangiopancreatography Market Segmentation
Endoscopic Retrograde Cholangiopancreatography Procedure Outlook Â
- Biliary Sphincterotomy
- Biliary Stenting
- Biliary Dilatation
- Pancreatic Duct Stenting
- Others
Endoscopic Retrograde Cholangiopancreatography End User OutlookÂ
- Hospitals & Clinics
- Ambulatory Surgical Centers
Endoscopic Retrograde Cholangiopancreatography Application Outlook Â
- Bile Duct
- Pancreas
- Others
Endoscopic Retrograde Cholangiopancreatography Product Outlook Â
Endoscopic Retrograde Cholangiopancreatography Regional Outlook Â
North America
Europe
Asia-Pacific
Rest of the World
Â
| Report Attribute/Metric |
Details |
| Market Size 2024 |
  2.28 (USD Billion) |
| Market Size 2025 |
  2.51 (USD Billion) |
| Market Size 2034 |
  5.82 (USD Billion) |
| Compound Annual Growth Rate (CAGR) |
  9.80 % (2025 - 2034) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2024 |
| Market Forecast Period |
2025 - 2034 |
| Historical Data |
2020 - 2024 |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Procedure, End User, Application, Product, and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered |
The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
Olympus Corporation (Japan), Fujifilm Holdings, Corporation (Japan), STERIS PLC (UK), Cook Medical (US), Boston Scientific Corporation (US), CONMED Corporation (US), HOYA Group (Japan), Q3 Medical Devices Limited (Ireland), Ambu Inc. (Denmark), Medtronic Plc (Ireland), and Others |
| Key Market Opportunities |
Rising demand for minimally invasive surgeries |
| Key Market Dynamics |
Increasing prevalence of gastrointestinal diseases (GIT) associated with the pancreas and bile ducts Technological advancements |
Endoscopic Retrograde Cholangiopancreatography Market Highlights:
Frequently Asked Questions (FAQ) :
The endoscopic retrograde cholangiopancreatography market size was valued at USD 1.9 Billion in 2022.
The market is projected to grow at a CAGR of 9.80% during the forecast period, 2023-2032.
North America had the largest share in the market
The key players in the market are Olympus Corporation (Japan), Fujifilm Holdings, Corporation (Japan), STERIS PLC (UK), Cook Medical (US), Boston Scientific Corporation (US), CONMED Corporation (US), HOYA Group (Japan), Q3 Medical Devices Limited (Ireland), Ambu Inc. (Denmark), Medtronic Plc (Ireland), and Others.
The bile duct category dominated the market in 2022.
The hospitals & clinics category had the largest share in the market.
